EKSO BIONICS HOLDING (OTCBB:EKSO) stated that Amy Wendell, former Senior VP of Strategy and Business Development Division of Covidien plc (NYSE:COV) has been elected to the company’s Board of Directors. Nathan Harding, the Co-founder and CEO said that Amy Wendell in her prior association with Covidien presided over an extraordinary acquisition plan acquiring over hundred companies with advance technologies across several healthcare segments.
She has planned and executed incredible number of growth plans and understands the strategies that really makes sense. The company looks forward to benefitting from her product and operational management experience as well as her sharp acumen.
The expert view
Steven Sherman who is the Chairman of EKSO BIONICS HOLDING (OTCBB:EKSO) said that the management was committed to finding a board member with all the characteristics that Wendell embodies for more than a year now. The management is proud to welcome such an exemplary individual. He added that he is confident Wendell is going to have a significant positive impact on the company.
Expressing her views on recent association with EKSO Wendell said that she had a long time inclination towards medical device technology. She always had a keen interest in guiding innovative firms to make a positive impact in everyone’s lives, achieve business milestones and extend into new markets. She added that she is thrilled by what Ekso has started to accomplish and she is honored to be joining the company’s board.
Since 1986, Wendell has served on various leadership positions at Covidien, where she led the company’s portfolio management and strategic planning operations, as well as all business development activities including M&A, equity investments, integrations, divestitures, distribution, licensing and market intelligence. The appointment of Wendell increases the Ekso Bionics’ board size to seven. In last trading session, the share price of EKSO dropped 1% to close the trading session at $1.99 on share volume of 280,140.